The Economist Novo Nordisk, maker of Ozempic and Wegovy, has become Europe’s most valuable company. Arriving in Stepford, Connecticut, Joanna – protagonist of The Stepford Wives, a horror novel–– is dragged to a “workout class” at the Simply Stepford Day Spa by a neighbour. The duo are met by 15 identikit women.
Their hair, heights and skin colours differ a little. Their waist sizes do not. Each can be no bigger than a British size 8, their waists nipped in by belts and accentuated by 1950s skirts.
As some describe it, this is where the world is now heading owing to the discovery of weight-loss drugs. In three short years since America’s Federal Drug Administration approved these medications, their use has exploded. Novo Nordisk, maker of Ozempic and Wegovy, has become Europe’s most valuable company.
Eli Lilly, which manufactures Mounjaro, was one of America’s best performers in 2023. And celebrities including Oprah Winfrey and Kelly Clarkson have emerged, almost overnight, slimmed down and svelte. Already a subscriber? Log in Get exclusive reports and insights with more than 500 subscriber-only articles every month $9.
90 $9.90/month No contract ST app access on 1 mobile device Subscribe now All subscriber-only content on ST app and straitstimes.com Easy access any time via ST app on 1 mobile device E-paper with 2-week archive so you won't miss out on content that matters to you Join ST's Telegram channel and get the latest breaking news delivered to you.
Read 3 articles and stand to win rewards Spin the wheel now.
Politics
The economics of thinness (Ozempic edition)
The pursuit of thinness, especially for young girls, has come at a great cost.